세계의 파국적 항인지질 항체 증후군 시장 : 규모, 점유율, 동향 분석 보고서 - 치료별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Catastrophic Antiphospholipid Syndrome Market Size, Share & Trends Analysis Report By Treatment (Anticoagulants, Immunosuppressive Therapy, Plasma Exchange Therapy), By End-use (Hospitals, Clinics), By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,545,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,981,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,853,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

파국적 항인지질 항체 증후군 시장의 성장과 동향 :

Grand View Research의 최신 보고서에 따르면 세계 파국적 항인지질 항체 증후군 시장 규모는 2030년까지 89억 9,000만 달러에 달할 것으로 예측되며, 2024년부터 2030년까지의 복합 연간 성장률(CAGR)은 10.7%로 성장할 것으로 예상됩니다.

이 시장은이 희귀하고 생명을 위협하는자가 면역 질환의 진단, 치료 및 관리와 관련된 다양한 측면을 포함합니다.

파국적 항인지질 항체 증후군(CAPS) 시장에서는 효과적인 치료 옵션에 대한 수요 증가가 중요합니다. 환자와 의료 제공업체는 급속한 진행과 다장기 병변 등 CAPS가 초래하는 특유의 과제를 해결할 수 있는 혁신적인 치료법을 적극적으로 요구하고 있습니다. 임상시험은 본 증후군과 관련된 심각한 혈전성 사건을 완화시키는 표적 요법의 개발에 중점을 둡니다.

자가면역 질환의 유병률 증가는 시장 성장을 가속할 것으로 예상됩니다. 자가면역 질환은 신체가 실수로 조직을 공격하는 비정상적인 면역 반응을 수반합니다. 자가면역 질환의 일종인 APS는 과민성 장 증후군(IBS)과 같은 소화기계 문제를 포함하여 합병증을 유발할 수 있습니다. 크론병,대장염 캐나다에 따르면 2023년에는 322,600명 이상의 캐나다인이 염증성 장질환(IBD)과 함께 생활하고 있는 것으로 추정되며, 이는 전체 인구의 약 0.82%에 해당합니다.

파국적 항인지질 항체 증후군 시장 보고서,하이라이트

• 치료법에 따르면 정맥 내 면역글로불린(IVIG) 부문은 2023년 36.93%의 최대 판매 점유율로 시장을 선도했습니다. IVIG의 효능은 난치성 CAPS 환자가 항응고 요법 및 코르티코스테로이드와 같은 다른 치료와 병용하여 이 치료를 받은 후에 개선을 보인 다양한 임상 사례에 의해 뒷받침됩니다.
• 최종 용도별로는 병원 분야가 2023년에 62.80%의 최대 매출 점유율로 시장을 견인했습니다. 자가면역질환의 유병률 증가나 의료 제공자의 사이에서 CAPS에 대한 인식이 높아지고 있기 때문에 적시 개입하는 것으로 환자의 결과를 대폭 개선해, 이 생명을 위협하는 질환과 관련된 사망 비율을 낮출 수 있기 때문에 병원 기반 관리에 대한 수요가 증가하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 파국적 항인지질 항체 증후군 시장의 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/부수시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 파국적 항인지질 항체 증후군 시장 분석 도구
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 파국적 항인지질 항체 증후군 시장 : 치료별 추정 및 동향 분석

• 세계의 파국적 항인지질 항체 증후군 시장 : 치료 대시보드
• 세계의 파국적 항인지질 항체 증후군 시장 : 치료 변동 분석
• 세계의 파국적 항인지질 항체 증후군 시장 : 치료별 수익
• 항응고제
• 면역억제요법
• 혈장 교환 요법(혈장 교환 요법)
• 정맥내 면역글로불린(IVIG)
• 기타 치료

제5장 파국적 항인지질 항체 증후군 시장 : 최종 용도별 추정 및 동향 분석

• 세계의 파국적 항인지질 항체 증후군 시장 : 최종 용도 대시보드
• 세계의 파국적 항인지질 항체 증후군 시장 : 최종 용도 변동 분석
• 최종 용도별 수익
• 병원
• 클리닉
• 기타

제6장 파국적 항인지질 항체 증후군 시장 : 치료 및 최종 용도별 지역별 추정 및 동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석(2018-2030년)
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제7장 경쟁 구도

• 기업/경쟁의 분류
• 벤더 상황
  • 주요 리셀러 및 채널 파트너 목록
  • 주요 기업의 시장 점유율 분석(2023년)
  • Pfizer
  • Abbott
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Boehringer Ingelheim International GmbH
  • Novartis AG
  • Merck KGaA
  • AbbVie Inc.
  • F. Hoffmann-La Roche
  • Johnson &Johnson Services, Inc.

BJH

영문 목차

영문목차

Catastrophic Antiphospholipid Syndrome Market Growth & Trends:

The global catastrophic antiphospholipid syndrome market size is anticipated to reach USD 8.99 billion by 2030 and is projected to grow at a CAGR of 10.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market encompasses various aspects related to the diagnosis, treatment, and management of this rare and life-threatening autoimmune disorder.

The rising demand for effective treatment options is critical in the catastrophic antiphospholipid syndrome (CAPS) market. Patients and healthcare providers are actively seeking innovative therapies that can address the unique challenges posed by CAPS, including its rapid progression and multi-organ involvement. The clinical trials are focused on developing targeted therapies that mitigate the severe thrombotic events associated with the syndrome.

The rising prevalence of autoimmune disorders is anticipated to drive the market growth. Autoimmune disorders involve an abnormal immune response where the body mistakenly attacks its tissues. APS, a type of autoimmune disease, can lead to complications, including digestive issues such as irritable bowel syndrome (IBS). According to Crohn's and Colitis Canada, over 322,600 Canadians were estimated to be living with inflammatory bowel disease (IBD) in 2023, which represents about 0.82% of the total population.

Catastrophic Antiphospholipid Syndrome Market Report Highlights:

• Based on treatment, the intravenous immunoglobulin (IVIG) segment led the market with the largest revenue share of 36.93% in 2023. The efficacy of IVIG is supported by various clinical instances where patients with refractory CAPS showed improvement after receiving this therapy, often in conjunction with other treatments such as anticoagulation and corticosteroids
• Based on end-use, the hospital segment led the market with the largest revenue share of 62.80% in 2023. The increasing prevalence of autoimmune diseases and the growing awareness of CAPS among healthcare providers fuel the demand for hospital-based care, as timely interventions can significantly improve patient outcomes and reduce mortality rates associated with this life-threatening condition

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. End Use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment Outlook
  • 2.2.2. End Use Outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Catastrophic Antiphospholipid Syndrome Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. The rising incidence of autoimmune diseases
    • 3.2.1.2. Advancements in diagnostic technologies
    • 3.2.1.3. Increased awareness and education about CAPS
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Limited awareness and understanding of CAPS
    • 3.2.2.2. Challenges in the diagnosis and treatment of CAPS
• 3.3. Catastrophic Antiphospholipid Syndrome Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Catastrophic Antiphospholipid Syndrome Market: Treatments Estimates & Trend Analysis

• 4.1. Global Catastrophic Antiphospholipid Syndrome Market: Treatments Dashboard
• 4.2. Global Catastrophic Antiphospholipid Syndrome Market: Treatments Movement Analysis
• 4.3. Global Catastrophic Antiphospholipid Syndrome Market by Treatments, Revenue
• 4.4. Anticoagulants
  • 4.4.1. Anticoagulants market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Immunosuppressive Therapy
  • 4.5.1. Immunosuppressive Therapy market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Plasma Exchange Therapy (Plasmapheresis)
  • 4.6.1. Plasma Exchange Therapy (Plasmapheresis) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Intravenous Immunoglobulin (IVIG)
  • 4.7.1. Intravenous Immunoglobulin (IVIG) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Other Treatment
  • 4.8.1. Other treatment market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Catastrophic Antiphospholipid Syndrome Market: End Use Estimates & Trend Analysis

• 5.1. Global Catastrophic Antiphospholipid Syndrome Market: End Use Dashboard
• 5.2. Global Catastrophic Antiphospholipid Syndrome Market: End Use Movement Analysis
• 5.3. Global Catastrophic Antiphospholipid Syndrome Market Estimates and Forecasts, By End Use, Revenue (USD Million)
• 5.4. Hospitals
  • 5.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Clinics
  • 5.5.1. Clinics market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Other
  • 5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Catastrophic Antiphospholipid Syndrome Market: Regional Estimates & Trend Analysis by Treatments, and End Use

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company/Competition Categorization
• 7.2. Vendor Landscape
  • 7.2.1. List of key distributors and channel partners
  • 7.2.2. Key company market share analysis, 2023
  • 7.2.3. Pfizer
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Abbott
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. Bristol-Myers Squibb Company
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. Eli Lilly and Company
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. Boehringer Ingelheim International GmbH
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. Novartis AG
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives
  • 7.2.9. Merck KGaA
    • 7.2.9.1. Company overview
    • 7.2.9.2. Financial performance
    • 7.2.9.3. Product benchmarking
    • 7.2.9.4. Strategic initiatives
  • 7.2.10. AbbVie Inc.
    • 7.2.10.1. Company overview
    • 7.2.10.2. Financial performance
    • 7.2.10.3. Product benchmarking
    • 7.2.10.4. Strategic initiatives
  • 7.2.11. F. Hoffmann-La Roche
    • 7.2.11.1. Company overview
    • 7.2.11.2. Financial performance
    • 7.2.11.3. Product benchmarking
    • 7.2.11.4. Strategic initiatives
  • 7.2.12. Johnson & Johnson Services, Inc.
    • 7.2.12.1. Company overview
    • 7.2.12.2. Financial performance
    • 7.2.12.3. Product benchmarking
    • 7.2.12.4. Strategic initiatives

관련자료